More about Jubilant Ingrevia Limited
Fundamentals for Jubilant Ingrevia Limited
Regulatory Filings for Jubilant Ingrevia Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Fundamentals for Jubilant Ingrevia Limited
Business Operations:
Sector: Basic MaterialsIndustry: Specialty Chemicals
Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Revenue projections:
JUBLINGREA's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 25.71298 |
| debtToEquity | 26.51000 |
| earningsGrowth | -0.32300 |
| revenueGrowth | -0.00500 |
| grossMargins | 0.47382 |
| operatingMargins | 0.07756 |
| trailingEps | 16.75000 |
| forwardEps | 23.42591 |
JUBLINGREA's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
JUBLINGREA's low Debt-to-Equity ratio suggests the company is minimally leveraged, with limited reliance on debt to finance its operations. This reduced financial risk positions the company for greater stability and financial health, appealing to investors who value conservative financial management.
Jubilant Ingrevia Limited's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.
Jubilant Ingrevia Limited's negative gross and operating margins suggest that the company is currently facing financial difficulties, as it is unable to cover production and operational costs. This could result in significant losses if not addressed.
JUBLINGREA's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that JUBLINGREA is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.
Price projections:
Jubilant Ingrevia Limited's stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.
Insider Transactions:
There were 2 transactions selling JUBLINGREA stock, with prevailing market price of 686.4500122070312.Jubilant Ingrevia Limited had 9 buy transactions, with market price at 721.272230360243 per share.The list of insider transactions is inconclusive, with no evident trend emerging to suggest a notable shift in company behavior or outlook.
Recommendation changes over time:
Analysts have shown a buy bias for JUBLINGREA, marking it as a favorable investment option. This could inspire investors to see JUBLINGREA as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction